Advanced

Cardiovascular co-morbidity in rheumatic diseases.

Turesson, Carl LU ; Jacobsson, Lennart LU and Matteson, Eric L (2008) In Vascular Health and Risk Management 4(3). p.605-614
Abstract
Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but... (More)
Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but clinically relevant, efficacy of atorvastatin treatment in RA adds to the evidence for important anti-inflammatory properties for statins. There is increased recognition of the need for structured preventive strategies to reduce the risk of CVD in patients with rheumatic disease. Such strategies should be based on insights into the role of inflammation in CVD, as well as optimal management of life style related risk factors. In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Tumor Necrosis Factor-alpha: antagonists & inhibitors, T-Lymphocytes: immunology, Rheumatic Diseases: immunology, Rheumatic Diseases: epidemiology, Systemic: immunology, Lupus Erythematosus, Systemic: epidemiology, Inflammation: physiopathology, Hydroxymethylglutaryl-CoA Reductase Inhibitors: therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors: pharmacology, Cardiovascular Diseases: prevention & control, Cardiovascular Diseases: immunology, Cardiovascular Diseases: epidemiology, Rheumatoid: epidemiology, Arthritis, Rheumatoid: immunology
in
Vascular Health and Risk Management
volume
4
issue
3
pages
605 - 614
publisher
Dove Press
external identifiers
  • pmid:18827910
  • scopus:48049110032
ISSN
1178-2048
language
English
LU publication?
yes
id
e9d6969f-2dc0-4117-ac9d-5b29a9ba2c28 (old id 1262652)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18827910?dopt=Abstract
date added to LUP
2008-11-06 15:10:02
date last changed
2017-04-23 04:33:25
@article{e9d6969f-2dc0-4117-ac9d-5b29a9ba2c28,
  abstract     = {Patients with rheumatic disorders have an increased risk of cardiovascular disease (CVD). This excess co-morbidity is not fully explained by traditional risk factors. Disease severity is a major risk factor for CVD in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Shared disease mechanisms in atherosclerosis and rheumatic disorders include immune dysregulation and inflammatory pathways, which are potential targets for therapy. Lessons from RA and SLE may have implications for future research on the pathogenesis of atherosclerotic vascular disease in general. Recent data indicate that suppression of inflammation reduces the risk of CVD morbidity and mortality in patients with severe RA. The modest, but clinically relevant, efficacy of atorvastatin treatment in RA adds to the evidence for important anti-inflammatory properties for statins. There is increased recognition of the need for structured preventive strategies to reduce the risk of CVD in patients with rheumatic disease. Such strategies should be based on insights into the role of inflammation in CVD, as well as optimal management of life style related risk factors. In this review, the research agenda for understanding and preventing CVD co-morbidity in patients with rheumatic disorders is discussed.},
  author       = {Turesson, Carl and Jacobsson, Lennart and Matteson, Eric L},
  issn         = {1178-2048},
  keyword      = {Tumor Necrosis Factor-alpha: antagonists & inhibitors,T-Lymphocytes: immunology,Rheumatic Diseases: immunology,Rheumatic Diseases: epidemiology,Systemic: immunology,Lupus Erythematosus,Systemic: epidemiology,Inflammation: physiopathology,Hydroxymethylglutaryl-CoA Reductase Inhibitors: therapeutic use,Hydroxymethylglutaryl-CoA Reductase Inhibitors: pharmacology,Cardiovascular Diseases: prevention & control,Cardiovascular Diseases: immunology,Cardiovascular Diseases: epidemiology,Rheumatoid: epidemiology,Arthritis,Rheumatoid: immunology},
  language     = {eng},
  number       = {3},
  pages        = {605--614},
  publisher    = {Dove Press},
  series       = {Vascular Health and Risk Management},
  title        = {Cardiovascular co-morbidity in rheumatic diseases.},
  volume       = {4},
  year         = {2008},
}